Retatrutide TRIUMPH-1 (2023) and TRIUMPH-2 (2024) TRIUMPH-1 (Jastreboff et al., NEJM 2023): 338 non-diabetic adults with obesity, 48 weeks at escalating doses: 12 mg dose: 24.2% weight loss 8 mg dose: 22.8% 4 mg dose: 17.5% Placebo: 2.1% TRIUMPH-2 (Rosenstock et al., Lancet 2024) confirmed effects in T2D patients with concurrent NAFLD improvement (hepatic fat reduction 54% at 24 weeks, 12 mg dose)
Personalized Guidance Through Precision Peptide Testing PlexusDx offers the Precision Peptide Genetic Test, which identifies individual variations in GLP-1 receptor signaling and metabolic pathways
In cardiovascular diseases, regular consumption of antioxidant foods, such as extra virgin olive oil, has been associated with a reduction in hepatic steatosis, lipid peroxidation, and vascular inflammation, effects that contribute significantly to endothelial protection and the prevention of atherosclerosis [86, 87]
CJC-1295 is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH) with tetrasubstituted modifications (D-Ala, Gln, Ala, Leu) that protect the peptide from degradation by the enzy